A multi-center study on the clinical effect of danazol in patients with IgA nephropathy is described. Two different doses of oral administration, including 200 mg or 300 mg per day, were employed in the present study. Urinalysis and measurements of complement components, i.e. C3 and C4, were performed before, and in the eighth and 20th week after the administration of danazol. It was demonstrated that 200 or 300 mg of danazol administration was effective in reducing the amount of proteinuria and in increasing the levels of serum complement components in the patients.
It is concluded that the administration of danazol may be useful for treatment of patients with IgA nephropathy. and C4 were measured by a laser nephelometer in the Tokai University
Hospital.
The normal value of serum C3 was 85 ± 15 mg/dl, and that of serum C4 was 35 ± 15 mg/dl. Creatinine clearance (CCr) was also examined before and after the study. Urinalysis for proteinuria and hematuria was also performed before, during and after the study in the control patients who were treated with dipyridamole. Total amounts of urine per day were calculated repeatedly using Urimate-P (Sumitomo Bakelite Co.
Ltd., Tokyo, Japan). Urimate-P is a plastic container to be divided into two parts. The urine is collected in the upper part and then 1/50 volume of the original urine is pourred into the lower part after turning on the cock. Since 1/50 of urine output for 24 hr was accurately obtained by Urimate-P, it is easy to quantitate the amounts of proteinuria per day in out patient clinic. On the other hand, none of the patients without administration of danazol showed disappearance of proteinuria during the study period. Furthermore, no patient whose proteinuria disappeared on administration of danazol showed reappearance of proteinuria up to one year after the treatment. No side effect was observed in any patient during administration of 200 mg of danazol. The proportion of patients with improvement in proteinuria after the administration of danazol was significantly greater than after dipyridamole administration. Administration of danazol was not effective in reducing the degree of hematuria in these patients.
IgA nephropathy is a well-recognized clinicopathologic entity that was first described by Berger 1969 . 
